Psyence Biomedical Ltd. (PBM) Common Equity (2023 - 2026)
Psyence Biomedical (PBM) posted quarterly Common Equity of $16.9 million for Q1 2026, up 152.07% year-over-year from $6.7 million in Q1 2025, and up 42.78% quarter-over-quarter from $11.9 million in Q3 2025.
Psyence Biomedical Ltd. (PBM) Common Equity (2023 - 2026) Analysis & Trends
Psyence Biomedical's Common Equity history runs 4 years deep, the most recent figure standing at $16.9 million for Q1 2026.
- In Q1 2026, Common Equity rose 152.07% year-over-year to $16.9 million; the TTM figure through Mar 2026 stood at $16.9 million (up 152.07% YoY), while the FY2026 annual figure was $16.9 million, up 152.07% from the prior year.
- Common Equity for Q1 2026 stood at $16.9 million, up from $11.9 million in the prior quarter.
- The five-year high for Common Equity was $16.9 million in Q1 2026, with the low at -$11.0 million in Q1 2024.
- The 4-year median for Common Equity is $2.9 million (2023), against an average of $3.7 million.
- The sharpest annual moves came in 2024 and 2025: Common Equity decreased 27.72% in 2024, then soared 1045.5% in 2025.
- Psyence Biomedical's Common Equity stood at -$982671.0 in 2023, then decreased by 27.72% to -$1.3 million in 2024, then jumped by 1045.5% to $11.9 million in 2025, then surged by 42.78% to $16.9 million in 2026.
- Business Quant data shows PBM's Common Equity at $16.9 million in Q1 2026, $11.9 million in Q3 2025, and $6.7 million in Q1 2025.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 16.94 Mn |
| Sep 30, 2025 | 11.87 Mn |
| Mar 31, 2025 | 6.72 Mn |
| Sep 30, 2024 | -1.26 Mn |
| Mar 31, 2024 | -10.97 Mn |
| Sep 30, 2023 | -982,671.00 |